Eric Lefkofsky is prominent for being the co-founder as well as the CEO of the famous Tempus. Tempus refers to a technology firm that has established a system of operation meant to aid cancer treatment. It is also worth acknowledging that he is also the Lightbank’s founding partner. Lightbank refers to an investment fund that ventures in troublesome technologies.
In consideration of Groupon (NASDAQ: GRPN), he occupies the position of the Chairman in addition to being the co-founder of the same company. The firm is often referred to as an international e-commerce market. He is also the co-founder of Uptake Technologies which is the best predictive platform of analytics for the largest firms globally. Others include Echo Global Logistics (NASDAQ: ECHO)which refers to a company that deals with technological transportation as well as the outsourcing of logistics. InnerWorkings which relates to an international provider of administered print as well as the remedies that offer promotion, and Mediocean which is the finest alongside the provision of incorporated media technology of procurement.
In the year 2006, Eric Lefkofsky together with Liz, his wife, set up the Lefkofsky Family Foundation. It refers to a private non-profit making platform established with the objective of advancing high-impact projects that facilitate the lives of those living in the societies served. Lefkofsky is currently a Trustee of The Art Institute of Chicago, Lurie Children’s Hospital of Chicago, World Business Chicago, The Museum of Science as well as Industry.
Additionally, Eric Lefkofsky is the Chairperson to the Trustees’ Panel of Steppenwolf Theatre Firm of Chicago. He is an assistant professor at the University of Chicago as well as Accelerated Disruption’s author. Looking into his education, he is a graduate of the University of Michigan. This happened before his attainment of Juris Doctor at the School of Law at the same University.
Being the founder of the great Groupon, Eric Lefkofsky is among the exclusively influential personalities in Chicago. He has given several millions of dollars to facilitate cancer-related research. At the moment, he is the one behind the establishment that aims at taking a smarter strategy towards the cure for cancer.
To know more visit @: www.chicagobusiness.com/article/20161001/ISSUE01/310019995/can-eric-lefkofsky-save-your-life
We all are subjected to different circumstances and situations while growing up. These diverse experiences help shape our future either consciously or unconsciously. The experiences have played a significant role in shaping the career choices of many youths. In addition, they act as a driving force towards the achievements of personal desires. A good example is the cancer researcher, Dr. Clay Siegall of Seattle Genetics, who made a career choice based on his experience when growing up.
Dr. Siegall’s career on the development of cancer therapies came about after experiencing the pain of watching a loved one suffer and ultimately die of the ailment. More so, Siegall had a soft spot for medicine from his childhood days. With the modern development in the technology world, the idea of practicing medicine with the help of these new ways charmed him the more, and he wanted to experience their power as they fought the dreaded diseases. At some point in his early twenties, his father was diagnosed with cancer, and he had to watch him suffer the seemingly brutal treatments that, to him, did more harm than good. Clay’s father later on died, and this made his desire more real. He resolved to search for better ways of treating the killer disease.
Dr. Clay Siegall is the founder and the CEO of Seattle Genetics. The biotech company specializes in the formulation of targeted cancer therapy drugs. He has seen his company develop proprietary drugs like the ADCs that have been effective. Through their sale, Clay has injected substantial revenues into the business, and it is now known all over. He attained a Bachelor of Science in Zoology from the University of Maryland and later earned a Ph.D. in Genetics from the University of George Washington.
Dr. Clay Siegall career at Seattle Genetics has been marked with remarkable success even though he has also worked in other reputable firms. He has rendered his unique services to Bristol-Myers Squibb Pharmaceutical Research Institute, the National Institute of Health, and also the National Cancer Institute. More so, he serves on the Board of Alder Bio-pharmaceuticals. Clay has also authored numerous scientific papers and holds more than 15 patents. His focus, hard work, and passion have been the drivers of his career success, and he advises other professionals to apply them in their operations.
The field of cancer research has been growing rapidly over the past few years as many research scholars and scientists are trying hard to determine the cure of this epidemically spreading terminal disease. Even though there have been many positive developments over the years, there is still immense scope for improvement and research left. Eric Lefkofsky, who is popularly known for co-founding GrouponInc, which is now worth well over $2.2 Billion, founded Tempus, to aggregate cancer-related data to help physicians and scientists provide better cancer therapies.
In a Fortune Brainstorm Health Conference held in San Diego and attended by the who’s who of the health and pharmaceutical industry, Mr Lefkofsky said that one of the components that are still missing in the field of cancer research is the collection of patient data at one place. And, it is this void that Tempus aim to fill with the use of advanced data mining and aggregation technology.
With the help of technology provided by Tempus, physicians and scientists researching on cancer therapies would now have easy access to clinical data, therapeutic data, molecular data, and patient response data, in one place. It would make things much easier to understand for the physicians who are trying hard to find out why one therapy works brilliantly on some patient and fails miserably on some other. There is always a correlation in data and the treatments provided, and with the help of data available at one place, it would become much easier to find the missing link. Click here to know more.
While giving an example at the conference, Eric Lefkofsky said to get data of how many patients took Herceptin in the past couple of years and how well they responded, the medical centers and hospitals would probably take months to aggregate and provide such data. However, Tempus would facilitate such data within minutes and ensure that such information is flowing freely among the researchers, making it easier for them to avoid any loopholes in their research and overcome any challenges posed by the lack of data. Eric Lefkofsky has founded several companies over the years, including VC firm Lightbank and media procurement technology company, Mediaocean. He is also the founder of Echo Global Logistics and InnerWorkings.
Eric Lefkofsky – Co-founder and CEO @ Tempus | Crunchbase
The cancer fighting firm, Tempus, which is from Erick Lefkofsky the founder of Groupon, will provide doctors from the University of Chicago with data that will assist in treating patients with breast cancer. Tempus, which is based in Chicago, have partnered with University of Chicago Medicine so as to offer molecular analysis and sequencing to breast cancer specialists at the Chicago. This data will help the doctors to come up with treatment plans that are personalized for patients. According to Tempus, the data will be analyzed from approximately one thousand patients who have breast cancer. This will assist both researchers and doctors in uncovering patterns that will predict the manner in which patients respond to the treatment.
Tempus has said that the goal of this data is to over time assist in enhanced patient outcomes and better treatment. DrOlufunmilayoOlopade, who is the professor of human genetics and medicine at the University of Chicago, stated that there is little data on cancer patients, although this type of cancer is one of the most popular forms of cancer. DrOlopade added that they were extremely excited in partnering with Tempus and that they were eager to support the initiative so as to create the biggest molecular data that is clinically annotated in breast cancer.
In order to assist doctors in making treatment decisions that are personalized and real-time, Tempus uses genomic sequencing and machine learning. Founded in 2015, Tempus has its headquarters in 600 W. Chicago.
Erick Lefkofsky serves as the CEO and co-founder of Tempus, which is a technology firm that fights cancer. He is also the co-founder of Lightbank which invests in disruptive technologies. Erick Lefkofsky works at Groupon where he serves as the Chairman and Co-founder. He is also the co-founder of Uptake Technologies, which provides predictive analytics to the largest industries in the world. Erick is the co-founder of Echo Global Logistics, InnerWorkings and Mediaocean. Erick Lefkofsky founded the Lefkofsky Family Foundation in 2006, which is a private charitable initiative. He studied at the University of Michigan and also the University of Michigan Law School where he acquired his Juris Doctor.
Eric Lefkofsky on Twitter.